Perrigo (PRGO) Announces Approval for Rx Cetirizine Syrup
More News related to PRGO
- Perrigo Company (PRGO) Acquires Laboratorios Diba for $25M
- Perrigo Acquires Mexican Manufacturer Laboratorios Diba, S.A.
- Perrigo Company to Present at the JMP Securities 2008 Healthcare Focus Conference
- Beacon Equity Issues Trade Alerts on Recent Analyst Upgrades: IAR, CAM, PRGO, UNP, WYE, IEX
- Perrigo Dismissed from Miconazole Patent Litigation
Perrigo Company (Nasdaq: PRGO) announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Syrup (Rx only), 1mg/mL. The product is comparable to McNeil Consumer Healthcare's Zyrtec(R) Syrup, 1mg/mL, indicated for the relief of symptoms associated with seasonal allergic rhinitis.
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.96Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
